Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22915921 | 0.69 | GLA (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL18538054 | 0.68 | ATM (0.33) | — | |
| SCHEMBL18540686 | 0.65 | ADORA2A (0.39) | MEN1KMT2AALDH1A1ADORA2AADORA2B | |
| SCHEMBL23562918 | 0.63 | — | — | |
| SCHEMBL21566642 | 0.63 | ADORA2A (0.37) | ADORA2AADORA2B | |
| SCHEMBL18540685 | 0.63 | MAPT (0.38) | MEN1KMT2AADORA2AADORA2B | |
| SCHEMBL14077457 | 0.63 | MEN1 (0.42) | MEN1KMT2AALDH1A1ADORA2AADORA2B | |
| SCHEMBL17673728 | 0.63 | NOS3 (0.30) | — | |
| SCHEMBL22025584 | 0.63 | MAPT (0.37) | ALDH1A1 | |
| SCHEMBL19099015 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988357-B2 | Methods for preparation of quinazoline derivatives | ARAXES PHARMA LLC (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | ARAXES PHARMA LLC | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190672-A1 | METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES | TTBK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK1 | MEN1 448/4885KMT2A 661/4885ALDH1A1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.